ArticleJournal of obstetrics and gynaecology of India2025
Immunohistochemical Diversity of Endometrial Carcinoma and Their Implications in Prognosis: A Prospective Clinicopathological Study in a Tertiary Care Hospital of Eastern India.
Article in Journal of obstetrics and gynaecology of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometrial cancer is the sixth most common cancer in women worldwide with gradually increasing incidence and mortality rate. The most recent classification of endometrial carcinoma (EC) with diagnostic flowchart includes both immunohistochemical and molecular markers for prognostic purpose and better management of endometrial cancer. In this study, we want to analyze various immunohistochemical (IHC) markers in EC and their prognostic significance. Methods: This was a prospective study conducted from August 2016 to February 2024. We studied 168 cases of EC for histopathological subtypes, grading and various IHC markers such as Estrogen Receptor (ER), Her 2 Neu, Cytokeratin 5/6, Epithelial Membrane Antigen (EMA) and p53. Results: In our study, most common histological subtype was endometrioid (132) followed by serous (17), mucinous (8), clear cell (7) and carcinosarcoma (4). ER expression was mostly seen in endometrioid type. Loss of ER expression and Her 2 expression along with p53 over expression was not only associated with high grade EC but also with advanced clinical stage and lymph node metastasis. Conclusion: Immunohistochemical markers play a definite role in risk stratification and specific individual oriented therapy in endometrial cancer patients. Supplementary Information: The online version contains supplementary material available at 10.1007/s13224-024-02046-9.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.